Jazz earnings for the third quarter of 2026 will include a $755 million expense tied to the company’s $1.32 billion acquisition of Actio Biosciences. Jazz Pharmaceuticals said on October 26 that the charge is expected to reduce both GAAP and non-GAAP adjusted earnings per share by $11.00.

Key Takeaways

  • Jazz projects a third-quarter GAAP loss of $0.69 per share and adjusted earnings of $1.97 per share.
  • The acquisition-related expense affects both earnings measures, rather than being excluded from adjusted EPS.
  • The full earnings release is scheduled for November 2, 2026, after market close.

Jazz earnings projections include the acquisition expense

The $755 million charge is expected to materially affect Jazz’s third-quarter results. With the expense included, the company projects GAAP earnings per share of negative $0.69 and non-GAAP adjusted earnings per share of $1.97.

These figures are preliminary projections ahead of the scheduled results release, not final reported earnings. The distinction between the two measures also remains important: Jazz expects a loss under GAAP but positive earnings on its adjusted basis.

Because the expense reduces both measures by the same stated $11.00 per share, the adjusted figure does not remove this particular acquisition-related impact.

Actio transaction sits alongside Jazz’s therapeutic portfolio

The expense is tied to the $1.32 billion Actio Biosciences acquisition. The charge and the transaction price describe different aspects of the deal: the former is the expected third-quarter earnings expense, while the latter is the acquisition’s stated value.

Jazz’s existing medicines portfolio spans rare sleep disorders, rare epilepsies and cancer. Its overview of therapeutic areas describes treatments for conditions including narcolepsy and rare epilepsies, alongside its oncology focus. That portfolio provides business context, separate from the preliminary earnings disclosure.

Next milestone

Jazz’s November 2, 2026 earnings release is the next scheduled milestone for the full third-quarter results.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.